Undisclosed Musculoskeletal
Articular Cartilage Injury
Discovery/PreclinicalActive
Key Facts
About Amphix Bio
Amphix Bio is a private, preclinical-stage biotech founded in 2021, leveraging a supramolecular chemistry platform to develop regenerative peptide therapeutics. The company has secured significant seed funding and multiple grants, with a pipeline focused on high-unmet-need neurological and musculoskeletal disorders. Key milestones include FDA Orphan Drug and Breakthrough Device designations for its acute spinal cord injury program, positioning it as an emerging player in the regenerative medicine space.
View full company profile